The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.

Chinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.

Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.

Over 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.

argenx and Zai Lab announced the approval of efgartigimod SC, a subcutaneous injection for the treatment of generalized myasthenia gravis in China. The approval is supported by positive results from the Phase 3 ADAPT-SC study, demonstrating consistent clinical benefit and safety profile compared to the intravenous formulation.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. BIOLASE, Inc. (NASDAQ: BIOL) On Jan. 29, Biolase reported full-year 2023 interim revenue of $48.9 million to $49.2 million, up 1% year-over-year compared to the consensus of $49.21 million. The company’s stock fell around 43% over the past five days ...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading after the company named Ismael Roig as Interim Chief Financial Officer. ADM also said it now expects an adjusted earnings per share of $6.90 for the fiscal year ended Dec. 2023. Archer-Daniels-Midland shares dipped 9.6% to $61.67 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. B. Riley Financial, Inc. (NASDAQ: RILY) shares tumbled 17.5% to $16.63 in pre-market trading. B. Riley Financial issued a statement in response ...

Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday. Shares of Paychex, Inc. (NASDAQ: PAYX) moved lower during Thursday’s session after the company reported worse-than-expected second-quarter revenue results and issued FY24 guidance. Paychex reported second-quarter FY24 sales growth of 6% year-on-year to $1.26 billion, slightly missing the analyst consensus estimate of $1.27 billion. Adjusted EPS of $1.08 beat the analyst consensus estimate of $1.07, according to Benzinga Pro. Paychex shares fell 5.4% to $120.96 on Thursday. Here are some other big stocks recording losses in today’s session. Jin Medical ...

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. bluebird bio shares rose 6.6% to $3.05 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 142.6% to $0.7399 after the company announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models. NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 79.4% to $0.7538 on continued volatility after the company last week received notification for not meeting the deadline to file its financial reports for several periods in 2023. Jet.AI Inc. (NASDAQ: JTAI) climbed 66% to $2.7550. The company recently posted a narrower quarterly loss. Assure Holdings Corp. (NASDAQ: IONM) gained 69.9% to $0.5950. Intchains Group Limited (NASDAQ: ICG) rose 25.8% to $11.02. Professional Diversity Network, Inc. (NASDAQ: IPDN) rose 23.3% to $2.64. Minim, Inc. (NASDAQ: MINM) gained 20% to $3.7450. MorphoSys AG (NASDAQ: MOR) rose 17.4% to $8.28 as the company presented comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib at 65th American Society of Hematology Annual Meeting. The Cigna Group (NYSE: CI) shares gained 16.8% to $302.25. Cigna has withdrawn from its proposed merger with Humana Inc. (NYSE: HUM). Macy's, Inc. (NYSE: M) rose 16.4% to $20.24. An investor consortium has tabled a $5.8 billion bid to acquire Macy's, in an attempt to privatize the iconic department store chain. Onconova Therapeutics, Inc. (NASDAQ: ONTX) shares rose 15.6% to $0.7421. Onconova Therapeutics' preclinical narazaciclib data at SABCS highlighted differentiated anti-tumor activity v. other CDK4/6i's. Dogness (International) Corporation ...

U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. Cogent Biosciences, Inc. (NASDAQ: COGT) shares tumbled 52.7% to $4.0803 after the company reported initial data from its ongoing Phase 2 SUMMIT trial and data from Part 1 of its ongoing Phase 2 APEX clinical at ASH 2023. Biomea Fusion, Inc. (NASDAQ: BMEA) shares dipped 32.2% to $11.40 after the company announced it presented data for BMF-219 in relapsed / refractory AML patients with menin-dependent mutations at the ASH 2023 Annual Meeting. XBP Europe Holdings, Inc. (NASDAQ: XBP) fell 25% to $12.00. Keros Therapeutics, Inc. (NASDAQ: KROS) declined ...

Over the past 3 months, 6 analysts have published their opinion on Zai Lab (NASDAQ:ZLAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 1 0 0 0 These 6 analysts have an average price target of $78.56 versus the current price of ...Full story available on Benzinga.com